TO DETERMINE THE OPTIMAL NEUROPROTECTIVE TREATMENT TYPE IN ISOLATED CLOSED HEAD INJURY VICTIMS BY COMPARATIVE COMPARISON OF STANDARD THERAPY AND KALLIDINOGENESIS.
Keywords:
closed head injury, tissue kallikrein (kallidinogenase), intracerebral hypertension, cerebral perfusion pressure, mean arterial pressure, M-echo pulsogram, coagulogram.Abstract
Closed head injury is a leading cause of morbidity, mortality, and disability in young and middle-aged adults. The most vulnerable group is comatose patients with severe traumatic brain injury. Kallidinogenase is a kallikrein-kinin system inhibitor that exerts neuroprotective effects on all neurons in the brain, inhibiting apoptosis, inflammation, oxidative stress, and excitotoxicity.
References
Alhenc-Gelas F, Bouby N, Richer C, et al. Kinins as therapeutic agents in cardiovascular and renal diseases. Curr Pharm Des 2011; 17:2654–2662.
2. Avakov V.E., Murotov T.M. Comparative characteristics of the effects of hyperosmolar therapy in patients with traumatic brain injury disser. 2021y.
3. Chen Z, Huang D, Niu F, et al. Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-kappaB. J Cereb Blood Flow Metab 2010; 30: 1356–1365.
4. Danhong Wu, Yi Lyu Ping Zhong Fengdi Liu Xueyuan Liu Human Urinary kallidinogenase promotes good recovery in ischemic stroke patients with level 3 hypertension Brain and Behavior. 2017;e00752.|1 of 4 https://doi.org/10.1002/brb3.752
5. Dong, Y., Wang, Y., Xie, Y., Dong, Q. (2020) Treatment with Human Urinary Kallidinogenase Improves Clinical Outcomes in Acute Ischemic Stroke Patients with Diabetes Mellitus. Curr Res Neurol Neurosurg, 3(1): 01-06.
6. Figueroa CD, Marchant A, Novoa U, et al.Differential distribution of bradykinin B2 receptors in the rat and human cardiovascular system. Hypertension 2001; 37: 110–120.
7. Gao L, Chao L and Chao J. A novel signaling pathway of tissue kallikrein in promoting keratinocyte migration: activation of proteinaseactivated receptor 1 and epidermal growth factor receptor. Exp Cell Res 2010; 316: 376–389.
8. Igic R. Four decades of ocular renin-angiotensin and kallikrein-kinin systems (1977-2017). Exp Eye Res. (2017) 166:74–83. doi: 10.1016/j.exer.2017.05.007
9. Krylov V.V. Surgery of severe traumatic brain injury. Under the general editorship of Krylova V.V. Moscow, 2019. 647 p.
10. Krylov V.V. Neurosurgery and neuroreanimatology. - M., 2018. - P. 137-154.
11. Menka Jha Ruchira. Intracranial Pressure Trajectories: a novel tool to inform severe BMJ phenotypes. Critical Care Medicine: January 2018 - Volume 46 - Issue 1 - p 16.
12. Michel A.K Rick Pols John. John J.W. Filip M. Batt and Todd A. Tkanevoy kalliykrien cheloveka pri lesheniy ostrovo ishiymisheskovo insulta.her Adv Neural Disord 2019. Vol 12: 1-15 DOI:10.1177/1756286418821918
13. Miao J, Deng F, Zhang Y, Xie HY, Feng JC. Exogenous Human Urinary Kallidinogenase Increases Cerebral Blood Flow in Patients with Acute Ischemic Stroke. Neurosci (Riyadh). 2016;21:126-30.
14. Norkulov A.Sh., Shodiev N.D., Ravshanov, S.N. To the features manifestation and treatment of mild craniocerebral trauma n.u. Problems of Biology and Medicine, 2016, issue 2 (87). UDK. 617.51-001-036.17-06-057.36-08.
15. Potapov A.A., Krylov V.V., Gavrilov A.G., Kravchuk A.D., Likhterman L.B. Guidelines for the diagnosis and treatment of severe traumatic brain injury. Part 2. Intensive care and neuromonitoring. Journal Problems of neurosurgery 1, 2016 98-106- pp doi: 10.17116/neiro201680198-106.
16. Potapov A.A. et al. Traumatic brain injury. Clinical guidelines, Moscow, 2001.
17. Regoli D and Gobeil F. Critical insights into the beneficial and protective actions of the kallikrein-kinin system/ Vascul Pharmacol 2015; 64: 1-10.
18. Raimondas J. Vaiva H. Pathophysiology of severe traumatic brain injury and management of intracranial hypertension. Lietuvos chirurgija. 2019, vol. 18(2), pp. 62–71
19. Ruchira M.J., Patrick M.K. et all. Pathophysiology and treatment of cerebral edema in traumatic brain injury. Neuropharmacology 145 (2019) 230–246.
20. Shalkevich L.V., Lvova O.A., Kulagin A.E., Talabaev M.V., Ivashina E.N., Sulimov A.V. Traumatic brain injury. Federal Guide to Pediatric Neurology edited by V.I. Guzeva. Moscow: MK, 2016. P. 361–377.
21. Sominov A. B., Lebedev I. A., Dreval O. N., Gaibov S. S-X, Zakharchuk E. V, Nekrasov N. A., Prevalence and structure of traumatic brain injury in a number of subjects of the Russian Federation, Ural Medical Journal, No. 10 (193) 2020, p. 156 - 159, DOI 10.25694/URMJ.2020.10.30
22. Simon Di Flippo, Antonio Messina. Eight rules of hemodynamic treatment of patients with traumatic brain injury. Eur J Anaesthesiol Intensive Care Med 2023; 2:4(e0029).
23. Tang LP, Benveniste EN, Law RM J Cereb Blood Flow Metab 19:819–34 (1995) Differential regulation of astrocyte TNF-alpha expression by the cytokines TGF-beta, IL-6 and IL-10. Int J Dev Neurosci 13:341–9.
24. Vasiliev D. Charkova Z. Combination of respiratory patterns of ventilation support modes for Correction of central perfusion pressure in patients with isolated severe Traumatic brain injury in the acute period. Wschodnioeuropejskie Czasopismo Naukowe (East European Scientific Journal) #9(61), 2020 p 4-18.
25. Whalley ET, Figueroa CD, Gera L, Bhoola, KD. Discovery and therapeutic potential of kinin receptor antagonists. Expert Opin Drug Discov. (2012) 7:1129–48. doi: 10.1517/17460441.2012.729038.
26. Wan F, J. Yang, J. Su et al., “Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-κB and activating Nrf2 signaling pathway in rats,” Experimental and ) terapeutic Medicine, vol. 14, no. 2, pp. 1163–1170, 2017.
27. Xia C-F, Smith RS, Shen B, et al. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 2006; 47: 752–761.
28. Xia C-F, Yin H, Yao Y-Y, et al. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther 2006; 17: 206–219.
29. Yang J, Su J, Wan F, et al. Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-κB and activating Nrf2 signaling pathway in rats. Exp Ther Med 2017; 14: 1163–1170.
30. Yang J, Su J, Wan F, et al. Tissue kallikrein protects against ischemic stroke by suppressing TLR4/NF-κB and activating Nrf2 signaling pathway in rats. Exp Ther Med 2017; 14: 1163–1170.
31. Zhang C, Tao W, Liu M, Wang D. Efficacy and Safety of Human Urinary Kallidinogenase Injection for Acute Ischemic Stroke: A Systematic Review. J Evid Based Med. 2012;5:31-39.
